Literature DB >> 2175464

Activity of human volunteer sera to candidate Plasmodium falciparum circumsporozoite protein vaccines in the inhibition of sporozoite invasion assay of human hepatoma cells and hepatocytes.

M R Hollingdale1, A Appiah, P Leland, V E do Rosario, D Mazier, S Pied, D A Herrington, J D Chulay, W R Ballou, T Derks.   

Abstract

Sera from human volunteers immunized with either synthetic peptide (NANP)3-TT or recombinant protein R32tet32 Plasmodium falciparum CS vaccines were tested in the inhibition of sporozoite invasion (ISI) assays using human hepatoma (HepG2-A16) cells or primary human hepatocytes. Sera or purified immunoglobulin (Ig) from volunteers who were completely protected against P. falciparum sporozoite challenge had higher ISI activity than sera from non-protected volunteers, or the highest titre endemic serum. However, Ig from protected and non-protected volunteers did not block sporozoite invasion of human hepatocytes, suggesting that P. falciparum sporozoites invade hepatocytes by mechanisms which differ from those concerned with invasion of HepG2-A16 cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2175464     DOI: 10.1016/0035-9203(90)90303-v

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  13 in total

1.  Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy.

Authors:  L F Fries; D M Gordon; R L Richards; J E Egan; M R Hollingdale; M Gross; C Silverman; C R Alving
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 2.  Controlled Human Malaria Infection: Applications, Advances, and Challenges.

Authors:  Danielle I Stanisic; James S McCarthy; Michael F Good
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

3.  Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo.

Authors:  K Brahimi; E Badell; J P Sauzet; L BenMohamed; P Daubersies; C Guérin-Marchand; G Snounou; P Druilhe
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

4.  Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A.

Authors:  L F Fries; D M Gordon; I Schneider; J C Beier; G W Long; M Gross; J U Que; S J Cryz; J C Sadoff
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.609

5.  Interferon-γ, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity.

Authors:  Blanca-Liliana Perlaza; Jean-Pierre Sauzet; Karima Brahimi; Lbachir BenMohamed; Pierre Druilhe
Journal:  Malar J       Date:  2011-02-08       Impact factor: 2.979

6.  Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.

Authors:  Ally Olotu; Philippe Moris; Jedidah Mwacharo; Johan Vekemans; Domtila Kimani; Michel Janssens; Oscar Kai; Erik Jongert; Marc Lievens; Amanda Leach; Tonya Villafana; Barbara Savarese; Kevin Marsh; Joe Cohen; Philip Bejon
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

7.  Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.

Authors:  Martha Sedegah; Cindy Tamminga; Shannon McGrath; Brent House; Harini Ganeshan; Jennylynn Lejano; Esteban Abot; Glenna J Banania; Renato Sayo; Fouzia Farooq; Maria Belmonte; Nalini Manohar; Nancy O Richie; Chloe Wood; Carole A Long; David Regis; Francis T Williams; Meng Shi; Ilin Chuang; Michele Spring; Judith E Epstein; Jose Mendoza-Silveiras; Keith Limbach; Noelle B Patterson; Joseph T Bruder; Denise L Doolan; C Richter King; Lorraine Soisson; Carter Diggs; Daniel Carucci; Sheetij Dutta; Michael R Hollingdale; Christian F Ockenhouse; Thomas L Richie
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

8.  Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.

Authors:  Aric L Gregson; Giane Oliveira; Caroline Othoro; J Mauricio Calvo-Calle; George B Thorton; Elizabeth Nardin; Robert Edelman
Journal:  PLoS One       Date:  2008-02-06       Impact factor: 3.240

Review 9.  Malaria vaccines: identifying Plasmodium falciparum liver-stage targets.

Authors:  Rhea J Longley; Adrian V S Hill; Alexandra J Spencer
Journal:  Front Microbiol       Date:  2015-09-15       Impact factor: 5.640

10.  Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparum.

Authors:  Xiaoyan Zou; Brent L House; Michael D Zyzak; Thomas L Richie; Vincent R Gerbasi
Journal:  Malar J       Date:  2013-11-05       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.